Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Major Depressive Disorder
Intervention: Pristiq first-line treatment charts (Other); Pristiq second-line treatment charts (Other); SNRI or SSRI first-line treatment charts (Other); SNRI or SSRI second-line treatment charts (Other)
Phase: Phase 4
Status: Completed
Sponsored by: Pfizer Official(s) and/or principal investigator(s): Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
The goal of this observational study is to learn about how Pristiq is currently being used
in general practice and how psychiatrists and primary care physicians currently perceive
Pristiq in terms of efficacy, tolerability, and adherence compared to other treatments for
major depressive disorder (MDD).
Clinical Details
Official title: A Retrospective Study To Evaluate The Current Utilization Of Desvenlafaxine Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
Study design: Time Perspective: Retrospective
Primary outcome: 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment.800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a SNRI or SSRI). 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a first-line treatment. 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
Secondary outcome: Incidence of adverse events and Incidence of discontinuation due to adverse eventsPercent of patients experiencing relapse Length of time to relapse Percent of discontinuation / medication switches due to lack of efficacy Subjective physician assessment of symptom control
Detailed description:
It is retrospective patient chart study among psychiatrists and primary care physicians
(PCPs) treating patients suffering from major depressive disorder (MDD). Physicians will be
asked general medical questions in order to quantify their prescribing behavior and their
perception of treatment performance. A retrospective patient chart review will then be
performed and patient data will be collected to document patient characteristics and actual
treatment outcomes. Upon qualification, specific instructions for chart review will be
provided. Once the identified charts are pulled, the physicians are instructed to continue
with the on-line survey. In total, there will be approximately 450 psychiatrists and 450
primary care physicians participating in this trial.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients must be adult, diagnosed with major depressive disorder and treated with
pharmacotherapy.
- Physicians must be either a psychiatrist or a primary care physician, a prescriber of
Pristiq, have at least 3 charts representing the 4 identified patient types, have
been in clinical practice between 4 and 35 years, primarily office based (50%+), not
participated in a research study relating to antidepressants or antidepressant
therapy within the past month, not a consultant or have a professional relationship
with a pharmaceutical company other than for clinical trials or speaking engagements,
and not be employed by of affiliated with an advertising agency, market research
company, or pharmaceutical company.
Exclusion Criteria:
- Patients who have not been treated for depression.
Locations and Contacts
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: September 2009
Last updated: January 25, 2011
|